JP2018518974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018518974A5 JP2018518974A5 JP2017567178A JP2017567178A JP2018518974A5 JP 2018518974 A5 JP2018518974 A5 JP 2018518974A5 JP 2017567178 A JP2017567178 A JP 2017567178A JP 2017567178 A JP2017567178 A JP 2017567178A JP 2018518974 A5 JP2018518974 A5 JP 2018518974A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- antigen recognition
- receptor
- cells
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 32
- 102000036639 antigens Human genes 0.000 claims 32
- 108091007433 antigens Proteins 0.000 claims 32
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 claims 21
- 102000004196 processed proteins & peptides Human genes 0.000 claims 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 19
- 229920001184 polypeptide Polymers 0.000 claims 19
- 101000795167 Homo sapiens Tumor necrosis factor receptor superfamily member 13B Proteins 0.000 claims 17
- 102100029675 Tumor necrosis factor receptor superfamily member 13B Human genes 0.000 claims 17
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 claims 14
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 13
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 13
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 13
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 13
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 12
- 102000010956 Glypican Human genes 0.000 claims 12
- 108050001154 Glypican Proteins 0.000 claims 12
- 108050007237 Glypican-3 Proteins 0.000 claims 12
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 12
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 12
- -1 LeY Proteins 0.000 claims 12
- 102100035721 Syndecan-1 Human genes 0.000 claims 12
- 102000013529 alpha-Fetoproteins Human genes 0.000 claims 12
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 12
- 230000000139 costimulatory effect Effects 0.000 claims 12
- 238000000034 method Methods 0.000 claims 12
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 11
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 11
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 11
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 11
- 101001005269 Arabidopsis thaliana Ceramide synthase 1 LOH3 Proteins 0.000 claims 10
- 101001005312 Arabidopsis thaliana Ceramide synthase LOH1 Proteins 0.000 claims 10
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 10
- 102100028801 Calsyntenin-1 Human genes 0.000 claims 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 10
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 10
- 101000633784 Homo sapiens SLAM family member 7 Proteins 0.000 claims 10
- 101000668858 Spinacia oleracea 30S ribosomal protein S1, chloroplastic Proteins 0.000 claims 10
- 101000898746 Streptomyces clavuligerus Clavaminate synthase 1 Proteins 0.000 claims 10
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 10
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 7
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 7
- 102100035248 Alpha-(1,3)-fucosyltransferase 4 Human genes 0.000 claims 6
- 102100022749 Aminopeptidase N Human genes 0.000 claims 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 6
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 claims 6
- 101001022185 Homo sapiens Alpha-(1,3)-fucosyltransferase 4 Proteins 0.000 claims 6
- 101000757160 Homo sapiens Aminopeptidase N Proteins 0.000 claims 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 6
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 claims 6
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 claims 6
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 claims 6
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 claims 6
- 101001008874 Homo sapiens Mast/stem cell growth factor receptor Kit Proteins 0.000 claims 6
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 claims 6
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 6
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 6
- 102100032999 Integrin beta-3 Human genes 0.000 claims 6
- 108010038501 Interleukin-6 Receptors Proteins 0.000 claims 6
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 6
- 102100025136 Macrosialin Human genes 0.000 claims 6
- 102100027754 Mast/stem cell growth factor receptor Kit Human genes 0.000 claims 6
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 claims 6
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 6
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 6
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 6
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 6
- 230000011664 signaling Effects 0.000 claims 6
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 5
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 102100024217 CAMPATH-1 antigen Human genes 0.000 claims 3
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 3
- 108010065524 CD52 Antigen Proteins 0.000 claims 3
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 3
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims 3
- 101000916644 Homo sapiens Macrophage colony-stimulating factor 1 receptor Proteins 0.000 claims 3
- 108010065805 Interleukin-12 Proteins 0.000 claims 3
- 108090000172 Interleukin-15 Proteins 0.000 claims 3
- 102100020789 Interleukin-15 receptor subunit alpha Human genes 0.000 claims 3
- 101710107699 Interleukin-15 receptor subunit alpha Proteins 0.000 claims 3
- 108010002350 Interleukin-2 Proteins 0.000 claims 3
- 108010002586 Interleukin-7 Proteins 0.000 claims 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 claims 3
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 3
- 239000003623 enhancer Substances 0.000 claims 3
- 108010074108 interleukin-21 Proteins 0.000 claims 3
- 108010083359 Antigen Receptors Proteins 0.000 claims 2
- 102000006306 Antigen Receptors Human genes 0.000 claims 2
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102100027208 T-cell antigen CD7 Human genes 0.000 claims 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000000581 natural killer T-cell Anatomy 0.000 claims 2
- 210000000822 natural killer cell Anatomy 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims 1
- 206010020631 Hypergammaglobulinaemia benign monoclonal Diseases 0.000 claims 1
- 208000001715 Osteoblastoma Diseases 0.000 claims 1
- 208000002774 Paraproteinemias Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 208000025750 heavy chain disease Diseases 0.000 claims 1
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims 1
- 208000031223 plasma cell leukemia Diseases 0.000 claims 1
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021167360A JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2024092213A JP2024116259A (ja) | 2015-06-25 | 2024-06-06 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562184321P | 2015-06-25 | 2015-06-25 | |
| US62/184,321 | 2015-06-25 | ||
| US201562235840P | 2015-10-01 | 2015-10-01 | |
| US62/235,840 | 2015-10-01 | ||
| US201562244435P | 2015-10-21 | 2015-10-21 | |
| US62/244,435 | 2015-10-21 | ||
| PCT/US2016/039306 WO2016210293A1 (en) | 2015-06-25 | 2016-06-24 | CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167360A Division JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018518974A JP2018518974A (ja) | 2018-07-19 |
| JP2018518974A5 true JP2018518974A5 (enExample) | 2019-07-18 |
| JP6961497B2 JP6961497B2 (ja) | 2021-11-05 |
Family
ID=57586695
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017567178A Active JP6961497B2 (ja) | 2015-06-25 | 2016-06-24 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2021167360A Active JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A Active JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2024092213A Pending JP2024116259A (ja) | 2015-06-25 | 2024-06-06 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021167360A Active JP7254870B2 (ja) | 2015-06-25 | 2021-10-12 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2023053851A Active JP7502515B2 (ja) | 2015-06-25 | 2023-03-29 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
| JP2024092213A Pending JP2024116259A (ja) | 2015-06-25 | 2024-06-06 | キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11655452B2 (enExample) |
| EP (1) | EP3313872A4 (enExample) |
| JP (4) | JP6961497B2 (enExample) |
| KR (1) | KR102968999B1 (enExample) |
| CN (2) | CN115058395B (enExample) |
| AU (3) | AU2016283102B2 (enExample) |
| CA (2) | CA3287691A1 (enExample) |
| IL (2) | IL287718B2 (enExample) |
| SG (1) | SG10201913682QA (enExample) |
| TW (1) | TWI833684B (enExample) |
| WO (1) | WO2016210293A1 (enExample) |
Families Citing this family (181)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201505858VA (en) | 2013-01-28 | 2015-09-29 | St Jude Childrens Res Hospital | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| EP3805371A1 (en) | 2014-05-15 | 2021-04-14 | National University of Singapore | Modified natural killer cells and uses thereof |
| AU2015357535B2 (en) | 2014-12-05 | 2020-05-14 | Eureka Therapeutics, Inc. | Antibodies targeting G-protein coupled receptor and methods of use |
| HRP20240357T1 (hr) * | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| PL3280729T3 (pl) | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| TWI833684B (zh) * | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| US11173179B2 (en) | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| US20220241327A1 (en) * | 2015-06-25 | 2022-08-04 | Icell Gene Therapeutics Llc | Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof |
| KR102157701B1 (ko) | 2015-08-17 | 2020-09-21 | 서울대학교산학협력단 | 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도 |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| CN109562126A (zh) | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| US11078481B1 (en) | 2016-08-03 | 2021-08-03 | KSQ Therapeutics, Inc. | Methods for screening for cancer targets |
| US12350349B2 (en) | 2016-08-03 | 2025-07-08 | Washington University | Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors |
| CN117298260A (zh) | 2016-09-02 | 2023-12-29 | 莱蒂恩技术公司 | 用DuoCAR治疗癌症的组合物和方法 |
| CA3042613A1 (en) * | 2016-11-11 | 2018-05-17 | Autolus Limited | Chimeric antigen receptor |
| CN110177803A (zh) * | 2016-11-22 | 2019-08-27 | T细胞受体治疗公司 | 用于使用融合蛋白进行tcr重新编程的组合物和方法 |
| EP3581190B1 (en) | 2016-12-09 | 2021-03-10 | ONK Therapeutics Limited | Engineered natural killer cells and uses thereof |
| CN110475857B (zh) | 2017-01-05 | 2023-07-18 | 韩国生命工学研究院 | 表达抗-可替宁嵌合抗原受体的天然杀伤细胞 |
| US20190375815A1 (en) * | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
| CA3051866A1 (en) * | 2017-02-01 | 2018-08-09 | Nant Holdings Ip, Llc | Calreticulin-mediated cancer treatment |
| CN110650624A (zh) * | 2017-03-10 | 2020-01-03 | 威斯康星州医药大学股份有限公司 | 用于视网膜疾病的核糖开关调节的基因治疗 |
| KR102708285B1 (ko) * | 2017-03-13 | 2024-09-20 | 포세이다 테라퓨틱스, 인크. | 조혈 줄기세포의 선택적 제거 및 대체를 위한 조성물 및 방법 |
| MX2019011570A (es) | 2017-03-27 | 2019-11-18 | Nat Univ Singapore | Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales. |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| WO2018193231A1 (en) * | 2017-04-18 | 2018-10-25 | Autolus Limited | Cell |
| JP2020517259A (ja) * | 2017-04-19 | 2020-06-18 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 操作された抗原受容体を発現する免疫細胞 |
| EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| AU2018269194B2 (en) * | 2017-05-15 | 2025-05-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors and their uses |
| PE20241587A1 (es) | 2017-06-02 | 2024-08-01 | Pfizer | Receptores de antigenos quimericos que se dirigen a flt3 |
| EP3635099A4 (en) * | 2017-06-07 | 2021-02-24 | The General Hospital Corporation | T-CELLS WITH EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR |
| US11241485B2 (en) | 2017-06-12 | 2022-02-08 | Obsidian Therapeutics, Inc. | PDE5 compositions and methods for immunotherapy |
| CN118853581A (zh) | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US12496310B2 (en) | 2017-06-30 | 2025-12-16 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy |
| WO2019006464A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS OF ADOPTIVE CELLULAR THERAPY AGAINST CANCER |
| WO2019006465A1 (en) | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY AGAINST CANCER |
| MX2019015505A (es) | 2017-06-30 | 2020-07-28 | Inscripta Inc | Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados. |
| US20200306301A1 (en) * | 2017-07-03 | 2020-10-01 | Torque Therapeutics, Inc. | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof |
| WO2019018525A1 (en) * | 2017-07-20 | 2019-01-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123 |
| WO2019067951A2 (en) * | 2017-09-29 | 2019-04-04 | Nantcell, Inc. | CD1D AND TCR-NKT CELLS |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| US11905528B2 (en) | 2017-10-12 | 2024-02-20 | Icell Gene Therapeutics Inc. | Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof |
| SG11202003415XA (en) | 2017-10-18 | 2020-05-28 | Novartis Ag | Compositions and methods for selective protein degradation |
| US11066475B2 (en) | 2017-11-01 | 2021-07-20 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides |
| US20210187024A1 (en) * | 2017-11-01 | 2021-06-24 | Nantkwest, Inc. | NK-92 Cells to Stimulate Anti-Cancer Vaccine |
| WO2019099639A1 (en) | 2017-11-15 | 2019-05-23 | Navartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
| MX2020005651A (es) | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
| US12139522B2 (en) | 2017-12-05 | 2024-11-12 | The Medical Research Infrastructure And Heal Serviced Fund Of The Tel Aviv Medecal Center | T-cells comprising two different chimeric antigen receptors and uses thereof |
| WO2019111249A1 (en) * | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
| WO2019136432A1 (en) | 2018-01-08 | 2019-07-11 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
| AU2019215031C1 (en) | 2018-01-31 | 2026-02-26 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
| WO2019165121A1 (en) | 2018-02-21 | 2019-08-29 | Board Of Regents, The University Of Texas System | Methods for activation and expansion of natural killer cells and uses therof |
| US12492254B2 (en) | 2018-02-23 | 2025-12-09 | H. Lee Moffitt Cancer Center and Research Intitute. Inc. | CD83-binding chimeric antigen receptors |
| KR20200130709A (ko) | 2018-03-06 | 2020-11-19 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 전립선-특이 막 항원 car 및 이의 사용 방법 |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| EP3773588A4 (en) * | 2018-04-09 | 2022-01-19 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF GRAFT VERSUS HOST DISEASES |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US10557216B2 (en) | 2018-04-24 | 2020-02-11 | Inscripta, Inc. | Automated instrumentation for production of T-cell receptor peptide libraries |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| EP3561053A1 (en) * | 2018-04-26 | 2019-10-30 | Baylor College of Medicine | Immune effector cells and molecular adaptors with an antigen cytokine complex for effective cancer immunotherapy |
| WO2019210280A1 (en) * | 2018-04-27 | 2019-10-31 | Casebia Therapeutics Limited Liability Partnership | Anti-bcma car-t-cells for plasma cell depletion |
| JP7599205B2 (ja) * | 2018-06-01 | 2024-12-13 | アンヘレス セラピューティクス インコーポレイテッド | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 |
| CN110577605A (zh) * | 2018-06-11 | 2019-12-17 | 浙江启新生物技术有限公司 | 一种靶向多发性骨髓瘤多种抗原的嵌合抗原受体t（car-t）细胞的构建方法及其应用 |
| CN110305847B (zh) * | 2018-07-27 | 2021-05-18 | 赛诺生（深圳）基因产业发展有限公司 | 一种用于治疗肿瘤的基因工程细胞 |
| EP3830114A4 (en) * | 2018-07-31 | 2022-08-03 | Washington University | USE OF INTERLEUKIN-7 AND CHIMERA ANTIGEN RECEPTOR (CAR) IMMUNE EFFECTOR CELLS FOR TUMOR TREATMENT |
| KR102907902B1 (ko) * | 2018-08-01 | 2026-01-02 | 난트퀘스트, 인크. | 면역 요법의 안정한 유전적 변형을 위한 귀소 수용체 또는 사이토카인, 및 키메라 항원 수용체를 포함하는 4 시스트론 시스템 |
| WO2020033585A1 (en) * | 2018-08-07 | 2020-02-13 | The Broad Institute, Inc. | Methods for combinatorial screening and use of therapeutic targets thereof |
| GB201813178D0 (en) * | 2018-08-13 | 2018-09-26 | Autolus Ltd | Cell |
| IL292273B2 (en) | 2018-08-14 | 2023-10-01 | Inscripta Inc | Devices, modules and methods for improved detection of edited sequences in living cells |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| CN109306016B (zh) * | 2018-08-15 | 2021-10-22 | 华东师范大学 | 共表达细胞因子il-7的nkg2d-car-t细胞及其用途 |
| WO2020044239A1 (en) | 2018-08-29 | 2020-03-05 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US20210171909A1 (en) | 2018-08-31 | 2021-06-10 | Novartis Ag | Methods of making chimeric antigen receptor?expressing cells |
| SI3844267T1 (sl) | 2018-08-31 | 2025-10-30 | Novartis Ag | Postopki izdelave celic, ki izražajo receptorje himernega antigena |
| WO2020061048A1 (en) * | 2018-09-17 | 2020-03-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses |
| WO2020061796A1 (en) * | 2018-09-26 | 2020-04-02 | Hrain Biotechnology Co., Ltd. | Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US20210338729A1 (en) * | 2018-10-12 | 2021-11-04 | Icell Gene Therapeutics Llc | CHIMERIC ANTIGEN RECEPTORS (CARs) COMPOSITIONS AND METHODS OF USE THEREOF |
| CA3116138A1 (en) * | 2018-10-17 | 2020-04-23 | Senti Biosciences, Inc. | Combinatorial cancer immunotherapy |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| KR20240162586A (ko) | 2018-10-31 | 2024-11-15 | 난트퀘스트, 인크. | Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거 |
| US12264189B2 (en) | 2018-10-31 | 2025-04-01 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| KR20200119892A (ko) * | 2018-10-31 | 2020-10-20 | 난트퀘스트, 인크. | Cd19-car 발현 nk 세포에 의한 cd19-양성 림프성 악성종양의 제거(elimination of cd19-positive lymphoid malignancies by cd19-car expressing nk cells) |
| US12624086B2 (en) | 2018-10-31 | 2026-05-12 | Mayo Foundation For Medical Education And Research | Materials and methods for treating cancer |
| US12257286B2 (en) | 2018-10-31 | 2025-03-25 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| US12473345B2 (en) | 2018-11-01 | 2025-11-18 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| US20220033848A1 (en) * | 2018-11-19 | 2022-02-03 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| CN113226340A (zh) * | 2018-11-26 | 2021-08-06 | 恩卡尔塔公司 | 同时扩增多种免疫细胞类型的方法、相关组合物及其在癌症免疫疗法中的用途 |
| AU2019388876A1 (en) * | 2018-11-26 | 2021-05-20 | Immunitybio, Inc. | IL-2 Dependent NK-92 cells with stable Fc receptor expression |
| KR20250116790A (ko) * | 2018-12-12 | 2025-08-01 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| WO2020124021A1 (en) | 2018-12-13 | 2020-06-18 | The General Hospital Corporation | Chimeric antigen receptors targeting cd79b and cd19 |
| EP3908613A4 (en) * | 2019-01-07 | 2022-10-19 | Celluris Participações Ltda. | BISPECIFIC IN-TANDEM RECEPTOR CAR AND METHODS FOR MODULATION OF THE TUMOR MICROAREA |
| CA3130489A1 (en) * | 2019-02-18 | 2020-08-27 | Memorial Sloan-Kettering Cancer Center | Combinations of multiple chimeric antigen receptors for immunotherapy |
| US20220152150A1 (en) | 2019-02-25 | 2022-05-19 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| US12018061B2 (en) * | 2019-03-08 | 2024-06-25 | St Phi Therapeutics Co., Ltd. | Chimeric endocytic receptors and method of use thereof |
| US20220088073A1 (en) * | 2019-03-19 | 2022-03-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Chimeric antigen receptors with enhanced tumor infiltration |
| WO2020190902A1 (en) * | 2019-03-19 | 2020-09-24 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Chimeric antigen receptors with enhanced tumor infiltration |
| EP3942025A1 (en) | 2019-03-21 | 2022-01-26 | Novartis AG | Car-t cell therapies with enhanced efficacy |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| AU2020247900A1 (en) | 2019-03-25 | 2021-11-04 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| WO2020210678A1 (en) | 2019-04-12 | 2020-10-15 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
| WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
| WO2020219989A1 (en) * | 2019-04-26 | 2020-10-29 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| JP7711945B2 (ja) | 2019-04-30 | 2025-07-23 | センティ バイオサイエンシズ インコーポレイテッド | キメラ受容体及びその使用方法 |
| US12023354B2 (en) * | 2019-05-31 | 2024-07-02 | Case Western Reserve University | Targeting B cell activating factor receptor (BAFF-R) using ligand-based chimeric antigen receptor (CAR)-T cells |
| EP3953477A4 (en) | 2019-06-06 | 2022-06-22 | Inscripta, Inc. | HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING |
| AU2020286471B2 (en) * | 2019-06-07 | 2025-07-31 | The Trustees Of The University Of Pennsylvania | Dual CAR expressing T cells individually linked to CD28 and 4-1BB |
| EP3999079A4 (en) * | 2019-07-19 | 2024-04-03 | Memorial Sloan Kettering Cancer Center | Fusion polypeptide for immunotherapy |
| CN110452294B (zh) * | 2019-08-06 | 2020-08-07 | 复旦大学 | 五种铰链区及其嵌合抗原受体和免疫细胞 |
| CN114787182A (zh) * | 2019-08-13 | 2022-07-22 | 艾佩斯瑞生物制药公司 | 工程化的白细胞介素-2受体β激动剂 |
| AU2020334317A1 (en) | 2019-08-16 | 2022-04-07 | Janssen Biotech, Inc. | Therapeutic immune cells with improved function and methods for making the same |
| US12702708B2 (en) | 2019-08-21 | 2026-08-11 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| US20210128617A1 (en) * | 2019-08-27 | 2021-05-06 | The Trustees Of The University Of Pennsylvania | SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS |
| CN112442509A (zh) * | 2019-08-29 | 2021-03-05 | 爱博赛特生物治疗公司 | Cd19-cd20双特异性和双通道car-t及其使用方法 |
| CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
| JP2022548902A (ja) * | 2019-09-18 | 2022-11-22 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｂｃｍａ陽性腫瘍を標的とするためのナチュラルキラー細胞の操作方法 |
| US11203762B2 (en) | 2019-11-19 | 2021-12-21 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| JP7805928B2 (ja) | 2019-11-26 | 2026-01-26 | ノバルティス アーゲー | Ｃｄ１９及びｃｄ２２キメラ抗原受容体及びその使用 |
| WO2021108661A2 (en) * | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
| US20230272035A1 (en) * | 2019-12-05 | 2023-08-31 | Vycellix, Inc. | Modulators of the immune escape mechanism for universal cell therapy |
| WO2021126886A1 (en) | 2019-12-18 | 2021-06-24 | Inscripta, Inc. | Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
| WO2021146147A1 (en) * | 2020-01-13 | 2021-07-22 | Nkarta, Inc. | Bcma-directed cellular immunotherapy compositions and methods |
| KR20220131529A (ko) * | 2020-01-14 | 2022-09-28 | 신테카인, 인크. | 변경된 icd stat 신호전달을 갖는 cd122 |
| WO2021150970A1 (en) * | 2020-01-22 | 2021-07-29 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| CN115135370A (zh) | 2020-01-27 | 2022-09-30 | 因思科瑞普特公司 | 电穿孔模块和仪器 |
| US11230699B2 (en) | 2020-01-28 | 2022-01-25 | Immunitybio, Inc. | Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors |
| US20210238535A1 (en) * | 2020-02-02 | 2021-08-05 | Inscripta, Inc. | Automated production of car-expressing cells |
| AU2021217373A1 (en) * | 2020-02-05 | 2022-08-04 | Neoimmunetech, Inc. | Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| JP2023516008A (ja) | 2020-02-27 | 2023-04-17 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
| IL295878A (en) | 2020-02-27 | 2022-10-01 | Novartis Ag | Methods for producing cells expressing a chimeric antigen receptor |
| JP2023517011A (ja) | 2020-03-05 | 2023-04-21 | ネオティーエックス セラピューティクス リミテッド | 免疫細胞を用いて癌を治療するための方法および組成物 |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| CN115777017A (zh) * | 2020-05-06 | 2023-03-10 | 亘喜生物科技（上海）有限公司 | 用于t细胞工程改造的组合物及方法 |
| WO2021225399A1 (ko) * | 2020-05-08 | 2021-11-11 | (주)에스엠티바이오 | 암 치료를 위한 키메라 항원 수용체 |
| US12202882B2 (en) | 2020-05-08 | 2025-01-21 | Alpine Immune Sciences, Inc. | APRIL and BAFF inhibitory immunomodulatory proteins and methods of use thereof |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
| US20240261401A1 (en) * | 2020-05-29 | 2024-08-08 | Icell Gene Therapeutics Inc. | Engineered immune cells, compositions and methods thereof |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| EP4161536A4 (en) * | 2020-06-04 | 2024-08-14 | Carisma Therapeutics Inc. | Novel constructs for chimeric antigen receptors |
| US20230332104A1 (en) | 2020-06-11 | 2023-10-19 | Novartis Ag | Zbtb32 inhibitors and uses thereof |
| WO2022040586A2 (en) | 2020-08-21 | 2022-02-24 | Novartis Ag | Compositions and methods for in vivo generation of car expressing cells |
| GB202013477D0 (en) * | 2020-08-27 | 2020-10-14 | Quell Therapeutics Ltd | Nucleic acid constructs for expressing polypeptides in cells |
| CN116568812A (zh) * | 2020-09-08 | 2023-08-08 | 亘喜生物科技（上海）有限公司 | 用于t细胞工程化的组合物和方法 |
| EP4214314A4 (en) | 2020-09-15 | 2024-10-16 | Inscripta, Inc. | Crispr editing to embed nucleic acid landing pads into genomes of live cells |
| WO2022076256A1 (en) * | 2020-10-05 | 2022-04-14 | Icell Gene Therapeutics Llc | Engineered immune cells for immunotherapy using endoplasmic retention techniques |
| WO2022086620A1 (en) | 2020-10-20 | 2022-04-28 | The Methodist Hospital System | Psma-targeted immunotherapies for cancers |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| US20240000838A1 (en) * | 2020-11-30 | 2024-01-04 | Simcere Innovation, Inc. | Universal chimeric antigen receptor-expressing immune cells for allogeneic cell therapy |
| TW202233662A (zh) * | 2020-12-31 | 2022-09-01 | 大陸商亘喜生物科技（上海）有限公司 | 膜融合蛋白及其在免疫細胞中的應用 |
| CA3204158A1 (en) | 2021-01-04 | 2022-07-07 | Juhan Kim | Mad nucleases |
| WO2022150269A1 (en) | 2021-01-07 | 2022-07-14 | Inscripta, Inc. | Mad nucleases |
| CN112778427B (zh) * | 2021-01-29 | 2022-03-15 | 武汉思安医疗技术有限公司 | 双特异性cs1-bcma car-t细胞及其应用 |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
| CN112698037B (zh) * | 2021-03-25 | 2021-06-25 | 北京积水潭医院 | 一种检测多发性骨髓瘤治疗效果的抗体组合物及其试剂盒和应用 |
| AR125468A1 (es) | 2021-04-27 | 2023-07-19 | Novartis Ag | Sistema de producción de vectores virales |
| JP2024531910A (ja) * | 2021-08-04 | 2024-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | Ｌａｔ活性化キメラ抗原受容体ｔ細胞及びその使用方法 |
| EP4388000A1 (en) | 2021-08-20 | 2024-06-26 | Novartis AG | Methods of making chimeric antigen receptor?expressing cells |
| EP4433512A4 (en) * | 2021-11-19 | 2025-12-31 | Univ Pennsylvania | Genetically modified pan-leukocyte-specific CD45 antigen to facilitate T-lymphocyte therapy |
| CN114835820B (zh) * | 2022-04-14 | 2023-01-06 | 呈诺再生医学科技(珠海横琴新区)有限公司 | 用于基因改造的多能干细胞及、自然杀伤细胞的嵌合型Fc受体 |
| CN116574194A (zh) * | 2022-06-02 | 2023-08-11 | 深圳普瑞金生物药业股份有限公司 | 嵌合抗原受体及其用途 |
| CN115232217B (zh) * | 2022-07-04 | 2023-06-06 | 深圳市先康达生命科学有限公司 | 一种SynNotch结构及其应用 |
| GB202209920D0 (en) * | 2022-07-06 | 2022-08-17 | Autolus Ltd | Cell |
| JP2026519263A (ja) | 2022-10-26 | 2026-06-15 | ノバルティス アーゲー | レンチウイルス製剤 |
| KR102938027B1 (ko) * | 2022-11-11 | 2026-03-13 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
| KR102938028B1 (ko) * | 2022-11-11 | 2026-03-13 | 주식회사 유씨아이테라퓨틱스 | 유전자 조작된 세포 및 이의 용도 |
| CN121969385A (zh) | 2023-09-11 | 2026-05-01 | 丹娜-法伯癌症研究院 | 含有il-2变体以增强car t细胞的功能性的car-衔接子 |
| EP4574838A1 (en) | 2023-12-21 | 2025-06-25 | Vilnius University | Chimeric antigen receptor (car) with enhanced recruitment of signaling partners |
| CN121488047A (zh) * | 2024-07-15 | 2026-02-06 | 南京元迈细胞生物科技有限公司 | 腺病毒载体及其应用 |
| EP4763861A1 (en) | 2024-12-23 | 2026-06-24 | AvenCell Therapeutics Inc. | An engineered cell comprising an anti-cd19 and anti-cd20 chimeric antigen receptor, a nucleic acid or vector, a kit and their use |
| WO2026139825A1 (en) | 2024-12-23 | 2026-07-02 | Avencell Therapeutics Inc. | An engineered cell comprising an anti-cd19 and anti-cd20 chimeric antigen receptor, a nucleic acid or vector, a kit and their use |
| WO2026139826A1 (en) | 2024-12-23 | 2026-07-02 | Avencell Therapeutics Inc. | An engineered cell comprising a chimeric antigen receptor and a switchable chimeric antigen receptor, a kit and their use |
| EP4763223A1 (en) | 2024-12-23 | 2026-06-24 | AvenCell Therapeutics Inc. | An engineered cell comprising a chimeric antigen receptor and a switchable chimeric antigen receptor, a kit and their use |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6764681B2 (en) | 1991-10-07 | 2004-07-20 | Biogen, Inc. | Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US20030147865A1 (en) | 2002-02-07 | 2003-08-07 | Benoit Salomon | Cell therapy using immunoregulatory T-cells |
| US20080254027A1 (en) | 2002-03-01 | 2008-10-16 | Bernett Matthew J | Optimized CD5 antibodies and methods of using the same |
| JP4596916B2 (ja) | 2002-09-05 | 2010-12-15 | メディミューン，エルエルシー | Ｃｄ２拮抗薬を投与することによりｔ細胞悪性腫瘍を予防または治療する方法 |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| US20080299042A1 (en) | 2004-04-30 | 2008-12-04 | Biogen Idec Ma Inc. | Membrane Associated Molecules |
| US20050277587A1 (en) | 2004-06-10 | 2005-12-15 | Academia Sinica | CD7 as biomarker and therapeutic target for psoriasis |
| EP1777294A1 (en) * | 2005-10-20 | 2007-04-25 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins |
| WO2007120368A2 (en) | 2006-01-09 | 2007-10-25 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
| ES2437315T3 (es) | 2006-06-12 | 2014-01-10 | Janssen Biotech, Inc. | Método para la detección de actividad IL-16 y modulación de actividad IL-16 en base a niveles RANTES proxy |
| WO2008140477A2 (en) | 2006-11-02 | 2008-11-20 | Capon Daniel J | Hybrid immunoglobulins with moving parts |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| EP2389443B1 (en) | 2009-01-23 | 2018-11-14 | Roger Williams Hospital | Retroviral vectors encoding multiple highly homologous non-viral polypeptides and the use of same |
| WO2010132697A2 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treatment |
| BRPI1013927A2 (pt) | 2009-05-13 | 2016-04-05 | Genzyme Corp | métodos e composições para o tratamento de lúpus |
| EP2325322A1 (en) | 2009-11-23 | 2011-05-25 | 4-Antibody AG | Retroviral vector particles and methods for their generation and use |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP5897035B2 (ja) | 2010-12-14 | 2016-03-30 | ユニバーシティ オブ メリーランド，ボルチモア | 汎用の抗タグキメラ抗原受容体発現ｔ細胞及びがんを治療する方法 |
| WO2012154344A1 (en) | 2011-04-06 | 2012-11-15 | Sanbio, Inc. | Methods and compositions for modulating peripheral immune function |
| KR101870555B1 (ko) | 2011-08-23 | 2018-06-22 | 로슈 글리카트 아게 | T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법 |
| EP2814846B1 (en) * | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| IN2014DN10889A (enExample) * | 2012-07-13 | 2015-09-11 | Univ Pennsylvania | |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| US10117896B2 (en) * | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
| SG11201507026WA (en) * | 2013-02-06 | 2015-10-29 | Anthrogenesis Corp | Modified t lymphocytes having improved specificity |
| IL305629A (en) * | 2013-02-15 | 2023-11-01 | Univ California | Chimeric antigen receptor and methods of using it |
| WO2014130635A1 (en) * | 2013-02-20 | 2014-08-28 | Novartis Ag | Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells |
| ES2769574T3 (es) * | 2013-03-15 | 2020-06-26 | Michael C Milone | Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva |
| SI2997141T1 (sl) | 2013-05-13 | 2023-04-28 | Cellectis | CD19 specifični himerni antigenski receptor in njegova uporaba |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2920539C (en) | 2013-08-08 | 2024-01-02 | Cytune Pharma | Combined pharmaceutical composition |
| US20160250258A1 (en) | 2013-10-31 | 2016-09-01 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof |
| AP2016009222A0 (en) | 2013-11-04 | 2016-05-31 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| EP3858379A1 (en) | 2013-11-21 | 2021-08-04 | Autolus Limited | Cell |
| EP3097117B1 (en) | 2014-01-21 | 2023-10-04 | Novartis Ag | Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules |
| WO2015120180A1 (en) | 2014-02-05 | 2015-08-13 | The University Of Chicago | Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants |
| DK3105317T3 (en) | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| SG10201808811QA (en) | 2014-04-10 | 2018-11-29 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Method and compositions for cellular immunotherapy |
| EP3166968B1 (en) | 2014-05-02 | 2021-09-22 | The Trustees of the University of Pennsylvania | Compositions and methods of chimeric autoantibody receptor t cells |
| JP6682509B2 (ja) | 2014-05-14 | 2020-04-15 | カースゲン セラピューティクス リミテッドＣａｒｓｇｅｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するｔリンパ球 |
| WO2016014553A1 (en) | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
| EP3712171A1 (en) * | 2014-08-19 | 2020-09-23 | Novartis AG | Treatment of cancer using a cd123 chimeric antigen receptor |
| DK3186284T3 (da) | 2014-08-28 | 2022-05-09 | Bioatla Inc | Betinget aktive kimæriske antigenreceptorer til modificerede t-celler |
| AU2015330017A1 (en) * | 2014-10-07 | 2017-04-27 | Cellectis | Method for modulating car-induced immune cells activity |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| CA2977106A1 (en) * | 2015-02-27 | 2016-09-01 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof |
| PL3280729T3 (pl) * | 2015-04-08 | 2022-08-22 | Novartis Ag | Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19 |
| US20220241327A1 (en) * | 2015-06-25 | 2022-08-04 | Icell Gene Therapeutics Llc | Chimeric Antigen Receptor (CAR) Targeting Multiple Antigens, Compositions and Methods of Use Thereof |
| TWI833684B (zh) | 2015-06-25 | 2024-03-01 | 美商生物細胞基因治療有限公司 | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 |
| US20190135894A1 (en) * | 2015-06-25 | 2019-05-09 | iCell Gene Therapeuticics LLC | COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF |
| US11173179B2 (en) * | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| CN105087495B (zh) * | 2015-08-21 | 2016-04-27 | 深圳市茵冠生物科技有限公司 | 双嵌合抗原受体修饰的t淋巴细胞及其制备方法 |
| GB201518817D0 (en) | 2015-10-23 | 2015-12-09 | Autolus Ltd | Cell |
| US20180371052A1 (en) * | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
| CN109562126A (zh) * | 2016-06-24 | 2019-04-02 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(car)、组合物及其使用方法 |
| PL3896091T3 (pl) * | 2016-08-10 | 2024-04-29 | Legend Biotech Ireland Limited | Chimeryczne receptory antygenowe nakierowane na bcma i sposoby ich zastosowania |
| CN118853581A (zh) * | 2017-06-21 | 2024-10-29 | 美商生物细胞基因治疗有限公司 | 嵌合抗原受体(CARs)、组合物及其使用方法 |
| US11905528B2 (en) * | 2017-10-12 | 2024-02-20 | Icell Gene Therapeutics Inc. | Compound chimeric antigen receptor (cCAR) targeting multiple antigens, compositions and methods of use thereof |
| MX2020005651A (es) * | 2017-11-30 | 2020-10-28 | Novartis Ag | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. |
-
2016
- 2016-06-24 TW TW105120100A patent/TWI833684B/zh active
- 2016-06-24 EP EP16815399.7A patent/EP3313872A4/en active Pending
- 2016-06-24 IL IL287718A patent/IL287718B2/en unknown
- 2016-06-24 CA CA3287691A patent/CA3287691A1/en active Pending
- 2016-06-24 KR KR1020187002389A patent/KR102968999B1/ko active Active
- 2016-06-24 CN CN202210523997.3A patent/CN115058395B/zh active Active
- 2016-06-24 AU AU2016283102A patent/AU2016283102B2/en active Active
- 2016-06-24 JP JP2017567178A patent/JP6961497B2/ja active Active
- 2016-06-24 SG SG10201913682QA patent/SG10201913682QA/en unknown
- 2016-06-24 CN CN201680036459.4A patent/CN107849112B/zh active Active
- 2016-06-24 CA CA2990177A patent/CA2990177C/en active Active
- 2016-06-24 US US15/739,596 patent/US11655452B2/en active Active
- 2016-06-24 WO PCT/US2016/039306 patent/WO2016210293A1/en not_active Ceased
-
2017
- 2017-12-19 IL IL256410A patent/IL256410B/en unknown
-
2021
- 2021-05-28 AU AU2021203481A patent/AU2021203481B2/en active Active
- 2021-10-12 JP JP2021167360A patent/JP7254870B2/ja active Active
-
2023
- 2023-03-29 JP JP2023053851A patent/JP7502515B2/ja active Active
- 2023-09-22 AU AU2023233207A patent/AU2023233207B2/en active Active
-
2024
- 2024-06-06 JP JP2024092213A patent/JP2024116259A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019522973A5 (enExample) | ||
| Klein et al. | Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines | |
| Lorenzo-Herrero et al. | NK cell-based immunotherapy in cancer metastasis | |
| Sadelain | CAR therapy: the CD19 paradigm | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| Vinay et al. | 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy | |
| Birkholz et al. | Transfer of mRNA encoding recombinant immunoreceptors reprograms CD4+ and CD8+ T cells for use in the adoptive immunotherapy of cancer | |
| JP2020074776A5 (enExample) | ||
| JP2022109953A5 (enExample) | ||
| RU2015109631A (ru) | Способ и композиции для клеточной иммунотерапии | |
| JP2017513470A5 (enExample) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| TWI833684B (zh) | 嵌合抗原受體（ｃａｒ）、組合物及其使用方法 | |
| JP2017515464A5 (enExample) | ||
| JP2022550899A5 (enExample) | ||
| JP2020533301A5 (enExample) | ||
| JP2020517259A5 (enExample) | ||
| RU2018118652A (ru) | Химерные конструкции антитело/т-клеточный рецептор и их применения | |
| RU2016143388A (ru) | Экспрессия трансгенов, регулируемая лекарственным средством | |
| Ding et al. | Fusion proteins of NKG2D/NKG2DL in cancer immunotherapy | |
| JP2017506513A5 (enExample) | ||
| RU2017121115A (ru) | Генетически модифицированные гамма дельта т-клетки | |
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| JP2021534740A5 (enExample) | ||
| JP2019528769A5 (enExample) |